What the research found

Recent anti-amyloid monoclonal antibodies (lecanemab, donanemab) do slow cognitive decline in early Alzheimer's disease, but the magnitude is modest: they reduce the rate of decline by roughly 0.45–0.67 points on an 18-point cognitive scale over 18 months compared to placebo. The drugs work by clearing amyloid plaques from the brain, yet this mechanistic effect doesn't translate into meaningful cognitive recovery for most patients.

In contrast, a case report describes a patient with Lyme disease whose elevated phosphorylated tau (p-tau217) normalized after antibiotic treatment targeting the infection, accompanied by subjective improvements in memory and concentration. This suggests that in some cases, cognitive decline may reflect treatable underlying infection rather than primary neurodegeneration, and addressing the root cause could theoretically reverse biomarker abnormalities rather than merely slow decline.

Why it matters for you

If you're tracking cognitive biomarkers like p-tau or amyloid ratios, this distinction is critical. Most MyKine users optimising health focus on reversing dysfunction—improving sleep, managing infection, correcting deficiencies—rather than accepting slow decline. The conventional neurology pathway (MoCA screening → p-tau blood test → amyloid-clearing infusions) may miss modifiable contributors: chronic infections, sleep-disordered breathing, B12 status, mycotoxin exposure, or lipid intake. These are factors you can actually address through protocol changes.

The case report is tantalising precisely because it flipped the narrative: the biomarker improved substantially, not marginally. If cognitive decline in some patients stems from chronic infection or inflammation rather than irreversible amyloid accumulation, testing for and treating those causes could be higher-yield than monthly infusions. This reinforces why comprehensive screening (including Lyme serology, sleep studies, nutritional status) before pursuing pharmacological amyloid clearance might be pragmatic.

Caveats

• Single case report: One patient's improvement cannot establish causation or generalisability; anecdote, not evidence.
• No trial data: No randomised controlled trial compares infection-focused treatment to anti-amyloid drugs in cognitively declining patients.
• Different patient populations: The Lyme case involved confirmed active infection; most cognitive decline in older adults does not have a clear infectious trigger.
• Financial incentives noted but not quantified: The article describes revenue structures for infusion-based care; this is real but does not prove that prescribing is inappropriate in all cases.
• Anti-amyloid drug effects are real but modest: The slowdown in decline is genuine, just smaller than many patients hope for.